Humanized Multi-Organoid Disease Models operated by
Dedicated Organoid Competence Centers

abc biopply AG provides validated highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis humanized multi-organoid technology™ on clinically relevant disease models (e.g. oncology, neurology, hepatic, obesity etc.)

In addition, the technology allows us to custom tailor or design any disease model and than license it to our clients for in-house implementation and scale up.

Highlights of our Integrated Organoid Services:

- Preclinical assays: drug efficacy, safety, toxicology, IC50, dose response, relapse and resistance studies
- Disease models: oncology, neurology, hepatic, renal, and cartilage
- Custom-tailored model development and biomarker discovery
- Integrated preclinical services, from in vitro to in vivo, synchronized with   humanized mouse models via our partner Preclina

Together, these offerings enable faster, more reliable drug discovery while reducing reliance on animal testing.

abc biopply ag

Arne-Christian Faisst

This department focuses on identifying growth opportunities and building strategic partnerships to drive organizational success.

Business Development

This department conducts scientific research and develops innovative solutions to advance preclinical disease modeling.

abc biopply ag

Org chart

Teams

Business Development

Research and Development

Offices

abc biopply ag

Org chart

Teams

Business Development

Research and Development

Offices

Related companies